SEC Form 4 · accession 0001209191-15-043351

· CELG

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — see remarks

Period of report

May 13, 2015

Accepted (ET)

May 15, 2015 · 4:29 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000816284

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	May 13, 2015	M	6,160	$36.90	A	85,683	D
Common Stock	May 13, 2015	M	11,824	$59.235	A	97,507	D
Common Stock	May 13, 2015	M	8,324	$49.475	A	105,831	D
Common Stock	May 13, 2015	M	4,162	$36.465	A	109,993	D
Common Stock^F1	May 13, 2013	S	47,173	$115.00	D	62,820	D
Common Stock	holding	—	—		—	2,000	I	IRA Account
Common Stock	holding	—	—		—	1,639	I	401(k) Plan

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F3,F2	$36.96	May 13, 2015	M	6,160	D	—	Mar 1, 2022	Common Stock	6,160	0	D
Stock Option (right to buy)^F3,F2	$59.235	May 13, 2015	M	11,824	D	—	Apr 29, 2023	Common Stock	11,824	5,912	D
Stock Option (right to buy)^F3,F2	$49.475	May 13, 2015	M	8,324	D	—	Jan 28, 2023	Common Stock	8,324	4,162	D
Stock Option (right to buy)^F3,F2	$36.465	May 13, 2015	M	4,162	D	—	Apr 30, 2022	Common Stock	4,162	0	D

F1These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan.
F2The option was fully exercisable.
F3The option was issued pursuant to the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013).

Chief Executive Officer of Celgene Cellular Therapuetics